Skip to main content
OpenTrials

Clinical trial condition

Acromegaly

Explore clinical trials studying Acromegaly. Study availability and eligibility vary by location and protocol.

143 public trials 11 recruiting studies
Refine in advanced search Browse all conditions

Acromegaly trial results

Completed

A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide

NCT00234520

Conditions
Acromegaly, Bone Diseases, Bone Diseases, Endocrine, +8 more
Locations
  • Cliniques Universitaires Saint Luc Brussels, Belgium
  • UZ Gasthuisberg Leuven, Belgium
  • CHU de Liege Liège, Belgium
  • University Hospital, Charles University Kralove, Czechia
View all 33 locations
View Trial Details
Completed

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

NCT00234572

Conditions
Acromegaly, Bone Diseases, Bone Diseases, Endocrine, +8 more
Locations
  • Baptist Health System Inc Birmingham, Alabama, United States
  • Pituitary Center Los Angeles, California, United States
  • Northwestern Medical Facility Chicago, Illinois, United States
  • Johns Hopkins University School of Medicine Baltimore, Maryland, United States
View all 29 locations
View Trial Details
Completed

Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

NCT02060383

Conditions
Acromegaly, Bone Diseases, Bone Diseases, Endocrine, +14 more
Locations
  • Diabetes and Endocrine Associates La Mesa Location Multiple Locations, California, United States
  • LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219 Torrance, California, United States
  • Coastal Metabolic Research Centre SC Ventura, California, United States
  • East Coast Institute for Research East Coast Inst. for Res(ECIR) Jacksonville, Florida, United States
View all 43 locations
View Trial Details
Completed

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

NCT02396953

Conditions
Acromegaly, Bone Diseases, Bone Diseases, Endocrine, +8 more
Locations
  • Antwerp University Hospital Edegem, Belgium
  • Domaine Universitaire Sart Tilman Liège, Belgium
  • Fakultni nemocnice u sv. Anny v Brne Brno, Czechia
  • Fakultní nemocnice Hradec Králové (University Hospital Hradec) Hradec Králové, Czechia
View all 36 locations
View Trial Details
Completed

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects

NCT00701363

Conditions
Acromegaly, Bone Diseases, Bone Diseases, Endocrine, +8 more
Locations
  • Universidade Federal do Rio de Janeiro - Department of Internal Medicine - Section of Endocrinology - Neuroendocrine Research Center Rio de Janeiro, Brazil
  • Hospital das Clínicas de São Paulo - Internal Medicine - Neuroendocrine Unit - Division of Endocrinology and Metabolism São Paulo, Brazil
  • Arhus University Hospital - Department of Medicinsk AVd M Arhus C, Denmark
  • Righospitalet - University Department of Endocrinology & Internal Medicine P Copenhagen, Denmark
View all 44 locations
View Trial Details
Completed

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

NCT02493517

Conditions
Acromegaly, Bone Diseases, Bone Diseases, Endocrine, +8 more
Locations
  • Peking Union Medical College Hospital Beijing, China
  • West China Hospital, Sichuan University Chengdu, China
  • Fujian Provincial Hospital Fuzhou, China
  • The First Affiliated Hospital, Sun Yat-sen University Guangzhou, China
View Trial Details

Related conditions